Disease · MONDO_0005347
Trials91
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.
1 to 20 of 91
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03415152 | A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy | 3,000 | 2020-10-12 | History of Myocardial Infarction, Hypertriglyceridemia | OMEGA-3-ACID ETHYL ESTERS | Its record names the disease | ClinicalTrials.gov | |
| NCT01408303 | [E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL | Phase 3 | 646 | 2014-12-05 | Hypertriglyceridemia, Cardiovascular Disease | OMEGA-3-CARBOXYLIC ACIDS | Its record names the disease | ClinicalTrials.gov |
| NCT01350973 | Efficacy of TAK-085 in Participants With Hypertriglyceridemia | Phase 3 | 611 | 2016-09-20 | Hypertriglyceridemia | ICOSAPENT, OMEGA-3-ACID ETHYL ESTERS | Its record names the disease | ClinicalTrials.gov |
| NCT01350999 | Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia | Phase 3 | 503 | 2016-09-20 | Hypertriglyceridemia | ICOSAPENT, OMEGA-3-ACID ETHYL ESTERS | Its record names the disease | ClinicalTrials.gov |
| NCT00812955 | Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides | Phase 3 | 474 | 2012-08-01 | Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia | FENOFIBRIC ACID, ROSUVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT03011450 | Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment | Phase 3 | 471 | 2022-10-28 | Severe Hypertriglyceridemia | K-877 | Its record names the disease | ClinicalTrials.gov |
| NCT01242527 | Epanova® for Lowering Very High Triglycerides | Phase 2/3 | 399 | 2013-09-06 | Severe Hypertriglyceridemia | OMEGA-3-CARBOXYLIC ACIDS | Its record names the disease | ClinicalTrials.gov |
| NCT02009865 | Epanova® for Lowering Very High Triglycerides II (EVOLVE II) | Phase 3 | 379 | 2016-01-15 | Hypertriglyceridemia | OMEGA-3-CARBOXYLIC ACIDS | Its record names the disease | ClinicalTrials.gov |
| NCT00435045 | Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia | Phase 3 | 245 | 2009-05-12 | Hypertriglyceridemia | ATORVASTATIN, OMEGA-3-ACID ETHYL ESTERS | Its record names the disease | ClinicalTrials.gov |
| NCT04365400 | Assess Efficacy and Safety of Epeleuton in Patients With Hypertriglyceridemia and Type 2 Diabetes | Phase 2 | 233 | 2023-06-01 | Hypertriglyceridemia, Type 2 Diabetes | EPELEUTON | Its record names the disease | ClinicalTrials.gov |
| NCT01047683 | Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL | Phase 3 | 229 | 2022-04-25 | Hypertriglyceridemia | ICOSAPENT ETHYL | Its record names the disease | ClinicalTrials.gov |
| NCT00903409 | Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects | Phase 3 | 188 | 2009-08-04 | Hypertriglyceridemia | OMEGA-3-ACID ETHYL ESTERS, SIMVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02300233 | The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia | Phase 3 | 114 | 2022-04-13 | Hypertriglyceridemia | VOLANESORSEN | Its record names the disease | ClinicalTrials.gov |
| NCT03385239 | Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Participants With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) | Phase 2 | 114 | 2023-01-11 | Hypertriglyceridemia, Cardiovascular Diseases | OLEZARSEN | Its record names the disease | ClinicalTrials.gov |
| NCT03371355 | Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease | Phase 2 | 105 | 2021-02-01 | NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic | VUPANORSEN | Its record names the disease | ClinicalTrials.gov |
| NCT04177680 | Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia | Phase 2 | 100 | 2022-03-04 | Hypertriglyceridemia | ICOSAPENT ETHYL | Its record names the disease | ClinicalTrials.gov |
| NCT02944383 | A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia | Phase 2 | 91 | 2020-06-25 | Severe Hypertriglyceridemia, Mixed Dyslipidaemia | GEMCABENE | Its record names the disease | ClinicalTrials.gov |
| NCT04541186 | Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia | Phase 2 | 86 | 2024-07-25 | Severe Hypertriglyceridemia | PEGOZAFERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT02354976 | A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects. | Phase 2 | 78 | 2018-09-25 | Non-alcoholic Fatty Liver Disease (NAFLD, Hypertriglyceridemia | FENOFIBRATE | Its record names the disease | ClinicalTrials.gov |
| NCT01280604 | Effect of Fenofibrate Conversion on Triglyceride Levels in Patients on Statin Therapy | Not applicable | 66 | 2015-06-08 | Hyperlipidemias | FENOFIBRATE | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005347/trials